The primary aim was to study the risk of cardiovascular mortality in patients with differentiated thyroid carcinoma (DTC). Secondary aims were to evaluate all-cause mortality and explore the relation between thyroid-stimulating hormone (TSH; also known as thyrotropin) level and these outcome parameters.
INTRODUCTION
Thyroid carcinoma is the most common endocrine malignancy with more than 450 cases in the Netherlands and an estimated 33,600 new cases in the European Union each year. 1 The most frequent type is differentiated thyroid carcinoma (DTC), consisting of both papillary and follicular (including Hürthle cell) thyroid carcinoma. The prognosis is favorable, with 10-year overall survival rates of 80% to 95%. 2 Initial treatment generally consists of total thyroidectomy followed by iodine-131 ( 131 I; hereafter, radioiodine) ablation therapy to destroy residual microscopic thyroid carcinoma and facilitate early detection of recurrent or metastatic disease by measurement of serum thyroglobulin. To prevent recurrence, subsequent thyroid hormone suppression therapy (THST) to lower thyroid-stimulating hormone (TSH; also known as thyrotropin) by administration of exogenous thyroxine (T4) has been considered necessary in all patients with DTC for decades. 3 The rationale for lowering TSH by THST is that TSH is considered a growth factor for thyroid cancer cells.
Since the survival rate after DTC is high, there is increasing interest in possible harmful long-term effects of treatment. 4 Particularly, the use and the extent of THST have become controversial in recent years, 5 since THST may increase cardiovascular morbidity. Atrial fibrillation, impaired systolic and diastolic cardiac function, increased left ventricular mass, decreased arterial elasticity, and adverse metabolic and prothrombotic effects of long-term exposure to THST have been described in patients with DTC. [6] [7] [8] [9] [10] Although increased cardiac mortality has been reported in patients with subclinical hyperthyroidism who do not have DTC, 11 ,12 the few articles on the risk of cardiovascular mortality in patients with DTC do not suggest such an excess. [13] [14] [15] The optimal balance between decreasing the risk of recurrence and potential iatrogenic cardiovascular mortality by treatment with exogenous T4 has not yet been found and may differ between groups of patients depending on cancer stage and comorbidity. The European Thyroid Association (ETA) and the American Thyroid Association (ATA) recommend THST in intermediate-and high-risk patients 16, 17 because it improves cancer survival in this group. 18 For low-risk patients, a low-normal TSH is advocated after initial treatment, despite a lack of strong data for increased cardiovascular mortality induced by THST.
The primary aim of this study was to evaluate whether the risk of cardiovascular mortality is increased in patients with DTC who are treated with THST during a long-term follow-up. Secondary aims were to evaluate all-cause mortality and to explore the relation between the level of TSH suppression and these outcome parameters.
PATIENTS AND METHODS

Study Design and Population
In this retrospective cohort study, the long-term risk of cardiovascular and all-cause mortality was compared between a large single-center cohort of patients with DTC and age-and sex-matched controls from a large prospective population-based cohort study in the same geographic region. Patients with DTC diagnosed between January 1980 and June 2010 and treated with total thyroidectomy and radioiodine ablation at our hospital were included. Controls were derived from the general population subsample of the Prevention of Renal and Vascular End Stage Disease (PREVEND) study, as described earlier. 19 Because the PREVEND study consisted of study subjects between the ages of 28 and 75 years only, age 26 to 77 years was an inclusion criterion for patients with DTC. For each patient with DTC, three controls were randomly chosen from all available subjects with the same sex and age at time of DTC diagnosis or enrollment onto the PREVEND study (within a range of 2 years). Patients with DTC were scored according to the postoperative TNM classification. 20 Until 2006, the fifth edition of TNM Classification of Malignant Tumours was used 21 ; thereafter, the sixth edition of this classification was used. 22 Patients were classified according to the risk of recurrence of DTC: low (Tx-T2, Nx-N0, Mx-M0), intermediate (any T3 or N1 tumor), or high (any T4 or M1 tumor). The institutional review board of our hospital approved contacting patients in case of missing baseline data. According to Dutch law, no further approval for retrospective data collection and analysis was required. Analyses were performed on fully anonymized data sets.
Treatment and Follow-Up
All patients with DTC underwent treatment according to our local protocol as published. 23 The national Dutch guidelines were implemented in 2007. The main difference with the previous protocol is the increase in radioiodine treatment interval from 3 to 6 months. 24 A TSH level below the lower limit of the reference range was pursued in all patients with DTC until 2007. From 2007 onward, the TSH target level was less than 0.1 mU/L in all patients. After 2 years of follow-up, T4 therapy could be tempered to a TSH level of 1.0 mU/L in low-risk patients. TSH target level was less than 0.01 mU/L in patients with distant metastatic disease. Follow-up including serum thyroglobulin measurements was performed as previously described. 23 
TSH Measurements
Study Definitions
Baseline was defined as the date of DTC diagnosis for patients and the date of PREVEND study entry for controls. Survival time was defined as the time from baseline to the date a patient died, was lost to follow-up, or the patient's last assessment. For patients with DTC, the last assessment was between January 1, 2011, and June 15, 2011. Cutoff date for follow-up of the PREVEND study was January 1, 2009. Data collection consisted of history taking, physical examination, and questionnaires, and for the patients with DTC, a review of medical records in addition. At baseline, traditional cardiovascular risk factors were assessed: age, sex, body mass index (BMI), diabetes mellitus (DM), smoking, hypertension, hypercholesterolemia, and a history of cardiovascular disease, defined as a previous stroke, myocardial infarction, peripheral artery disease or revascularization procedure. BMI was calculated as weight in kilograms divided by squared height in meters. Patients and controls were classified as having hypertension, hypercholesterolemia, or DM on the basis of the presence of documented prescription of drugs to treat these conditions. For patients with DTC, all TSH values and data regarding cumulative radioiodine dose, adjuvant external neck radiotherapy, and systemic therapy were obtained as well.
Study Outcomes
The primary end point was cardiovascular mortality, defined as a cardiovascular event leading to or directly causing death. Qualifying cardiovascular events were ICD-10 codes I10-I99, which include myocardial infarction, stroke, abdominal aortic aneurysm, and pulmonary embolism. Secondary end points were all-cause mortality and the association between THST and outcome parameters.
Statistical Analysis
Data are presented as mean plus or minus standard deviation, geometric mean (and 95% CI), or median and interquartile range (IQR). Missing BMI data were imputed on the basis of a regression including group (cases or controls), age, and sex (five imputations). 26 The Kaplan-Meier method, logrank test, and multivariate Cox proportional hazards regression model were used to test differences between cohorts. Crude and multivariate models with adjustment for age, sex, BMI, DM, smoking, hypertension, hypercholesterolemia, and history of cardiovascular disease at baseline were used. Analyses were repeated after exclusion of imputed BMI data. A possible association between the level of TSH suppression and eventfree survival was explored in the DTC group. For each year of follow-up, the mean TSH level was defined as the geometric mean of all available TSH values that year. In case of a year without TSH measurements, the TSH value was interpolated on the basis of the TSH of the previous and of the following year. In case of a missing TSH in the first or last year of follow-up, the TSH of the following or previous year was used, respectively. TSH values dating from before radioiodine ablation therapy, periods of thyroid hormone withdrawal, or use of recombinant human TSH were excluded. The geometric mean TSH level during the entire follow-up was defined as the geometric mean of the mean TSH values per year. Kaplan-Meier curves were plotted according to the geometric mean TSH level, categorized into three categories (geometric mean TSH Ͻ 0.02, 0.02 to 0.2, and Ͼ 0.2 mU/L). Cox regression analysis was performed to explore the association between TSH level and outcome. The minus log-transformed geometric mean TSH level entered the crude model, followed by adjustment for age, sex, cardiovascular risk factors, DTC risk classification, histology, cumulative radioiodine dose, and neck radiotherapy. All tests were two sided, and a P value of less than .05 was considered significant. The IBM SPSS for Windows version 20.0 (IBM, Armonk, NY) software package was used. Relative variance index (RVI), fraction of missing information (FMI), and relative efficiency of multiple imputation were assessed with STATA 11.0 (STATA, College Station, TX). Figure 1 shows a flowchart of the study. Of the 606 patients with DTC included in the study, 524 were eligible for analysis. Eighty-two patients were excluded because baseline and follow-up data were not available. The general population subsample of the PREVEND study consisted of 3,432 participants from which 1,572 controls were selected. Baseline characteristics are provided in Table 1 . As a result of the matching procedure, mean age (Ϯ standard deviation) of 49 Ϯ 14 years and percentage of males (25.6%) were equal in both groups. Hypertension (17.7% v 11.5%) and DM (4.2% v 2.5%) were more common in patients with DTC compared with controls; current smoking was less common (22.9% v 29.7%); and median BMI, presence of hypercholesterolemia, and history of cardiovascular disease were comparable. Missing BMI values for 100 study subjects (67 patients with DTC; 33 controls) were imputed.
RESULTS
Baseline
Cardiovascular and All-Cause Mortality
Outcome data are provided in Table 2 . Median follow-up was 8.5 years (IQR, 4.1 to 15.9 years) for patients with DTC. A total of 110 patients was lost to follow-up after a median follow-up of 7.5 years (IQR, 2.9 to 15.1 years). During follow-up, 100 patients (19.1%) died, 22 (4.2%) as a result of cardiovascular disease, 39 (7.4%) as a result of DTC progression or recurrence, and 39 (7.4%) as a result of other/ unknown causes. Median follow-up for controls was 10.5 years (IQR, 9.9 to 10.9 years). A total of 295 controls were lost to follow-up after a median follow-up of 8.7 years (IQR, 4.8 to 9.7 years). During followup, 85 controls (5.4%) died, 24 (1.5%) as a result of cardiovascular causes and 61 (3.9%) as a result of other/unknown causes. Median cumulative radioiodine dose for patients with DTC was 200 mCi (range, 55 to 426 mCi). Thirty-five patients with DTC (6.7%) underwent adjuvant neck radiotherapy for local uncontrolled disease, usually with a radiation dose of 50 to 70 Gray. None of the five patients (1.0%) with progressive distant metastatic disease who were systemically treated with sorafenib, a tyrosine kinase inhibitor, died as a result of a cardiovascular cause. No other systemic therapies, including doxorubicin, were administered.
Kaplan-Meier curves for both end points are shown in Figure 2 . Cardiovascular and all-cause mortality were significantly increased in patients with DTC compared with controls (log-rank P ϭ .012 and P Ͻ .001, respectively). In the unadjusted Cox regression model, the hazard ratio (HR) of cardiovascular mortality was 2.33 (95% CI, 1.18 to 4.58) for patients with DTC (Table 3) . After adjustment for age, sex, and cardiovascular risk factors, the HR was 3.35 (95% CI, 1.66 to 6.74). In the crude model, the HRs for all-cause mortality for patients with DTC were 3.15 (95% CI, 2.28 to 4.37) and 4.40 (95% CI, 3.15 to 6.14) after adjustment for age, sex, and cardiovascular risk factors. Results remained unchanged after repeated analysis without the imputed BMI data. Figure 3 shows the Kaplan-Meier curves of cardiovascular and all-cause mortality by TSH categories in patients with DTC. Cardiovascular and all-cause mortality were both affected by TSH category (log-rank P Ͻ .001 and P Ͻ .001, respectively). Further analyses of the association between TSH level and outcome are provided in Table 4 . In the crude model, each 10-fold decrease in geometric mean TSH level was associated with an HR of 2.95 (95% CI, 1.32 to 6.59) for cardiovascular and 2.57 (95% CI, 1.75 to 3.79) for all-cause mortality. After adjustment for age, sex, cardiovascular risk factors, DTC risk classification, histology, cumulative radioiodine dose, and neck radiotherapy, TSH level significantly predicted cardiovascular mortality with an HR of 3.08 (95% CI, 1.32 to 7.21); not all-cause mortality: HR, 1.43 (95% CI, 0.97 to 2.12).
Exploratory Analyses in the DTC Group
DISCUSSION
This study shows that the risk of cardiovascular mortality is 3.3-fold increased and the risk of all-cause mortality is 4.4-fold increased in patients with DTC compared with controls, independent of age, sex, and cardiovascular risk factors. Each 10-fold decrease in geometric mean TSH level is independently associated with a 3.1-fold increased risk of cardiovascular mortality. To the best of our knowledge, this is the first study reporting an increased risk of cardiovascular mortality in patients with DTC. Previous studies focused on DTC deaths and life expectancy in patients with DTC. Eustatia-Rutten et al 13 did not find an increased risk of cardiovascular mortality in a study of 366 patients with DTC with a mean follow-up of 8.3 years. The main explanation for the different outcome is that they included a relatively high-risk group of patients with DTC (T4 or M1 tumors) with a higher accompanying risk of death as a result of DTC, potentially concealing an increased risk of cardiovascular mortality. Furthermore, standardized mortality ratios based on Dutch sex-and age-specific mortality rates were used. This inevitably means a comparison with persons at increased risk for all-cause and cardiovascular mortality by other disease, thereby impeding the assessment of the effect of having had DTC and subsequent therapy only. Furthermore, we adjusted for the presence of cardiovascular risk factors but Eustatia-Rutten et al 13 did not. In an earlier study of 504 patients with DTC, of whom a large proportion was also included in this study, the frequency of cardiac death was comparable to that of the general Dutch population. 14 Standardized survival time was used, and the study focused on life expectancy following DTC, not on long-term cardiovascular mortality. The different statistical method, end point, and data acquisition methods can explain the discrepancy with our results. Another study reporting cardiovascular mortality cannot easily be compared, because median follow-up in this study was only 48 months, and no standardized treatment or follow-up was described. 15 Yang et al 27 recently published a comprehensive nomogram predicting the probability of death in patients with thyroid cancer, derived from a large data set of 29,225 patients. Cardiac and cerebrovascular disease were observed to be the most frequent causes of noncancer mortality. 27 Our results are an important addition to the data of Yang et al, 27 because we report that cardiovascular mortality is increased in patients with DTC compared with Abbreviations: BMI, body mass index; DM, diabetes mellitus; DTC, differentiated thyroid carcinoma; HR, hazard ratio.
matched controls, independent of age, sex, and cardiovascular risk factors. Moreover, we report that a lower TSH level is independently associated with increased cardiovascular mortality in these patients. The pathophysiological mechanism for increased cardiovascular mortality remains unknown. An increased risk for atrial fibrillation, impaired diastolic function, and an increased left ventricular mass have been found in patients with DTC receiving THST. 6, 8, 9 Induction of these adverse cardiovascular effects during THST may lead to an increased risk for stroke, heart failure, and myocardial infarction, respectively, and possibly contribute to the increased cardiovascular mortality. In patients with breast cancer, local adverse effects of radiation on coronary arteries have been described. 28 In our study, neither cumulative radioiodine dose nor external neck radiotherapy were related to primary outcome. Several limitations require comment. Although the observation of increased cardiovascular and all-cause mortality is clear, the design of an observational study does not allow us to draw any conclusions about possible causal relations between adverse outcome and the associated factors. However, our results do support the current ETA and ATA guidelines of tempering THST in patients with DTC with low risk of recurrence. The sources for the causes of death among patients with DTC and controls differ. Statistics Netherlands was the source for controls, whereas cause of death was ascertained by assessment of medical records and contact with the general practitioner for patients with DTC. Although it is unlikely that this has resulted in misclassification of study subjects who have died or those who are alive, the cause of death as reported by Statistics Netherlands or the patient record and general practitioner may not be fully in accordance with each other. Therefore, the results of the analyses of all-cause mortality may be more robust than those for cardiovascular mortality. Another methodologic issue is the different TSH assays used over time. However, this is inevitable with evolving laboratory techniques. We expect limited influence on the results, since the lower limits of the reference ranges are close together. Both hypertension and DM were more prevalent in the DTC group at baseline compared with controls and could contribute to the higher incidence of (cardiovascular) mortality in the DTC group. However, after adjustment for these conditions, the risk of cardiovascular and all-cause mortality remained increased. The increased prevalence of hypertension and DM in patients with DTC may result from possibly more stringent medical care with earlier recognition and treatment of these conditions. A consequence of the definitions of hypertension and hypercholesterolemia is that the influence of cardiovascular risk factors on outcome may be overestimated because patients with hypertension or hypercholesterolemia without additional risk factors are less likely to receive treatment, and therefore were not classified as having these conditions. Furthermore, secular trends in the treatment of cardiovascular diseases may have caused bias. To explore this, we repeated the analyses after exclusion of patients with DTC who were diagnosed before 1990. Results remained unchanged. Finally, the external validity of the results may be limited to patients with DTC with similar treatment algorithms in a nonwhite population.
Still, this is the first study to report an increased risk of cardiovascular and all-cause mortality in a large number of patients with DTC with a long follow-up, independent of age, sex, and cardiovascular risk factors. A lower TSH level is independently associated with an increased risk of cardiovascular mortality. These results therefore provide important data to support the current ETA and ATA guidelines of lowering THST in patients with a low risk of cancer recurrence. Furthermore, these results stress the importance of a close follow-up and could encourage assessment and treatment of cardiovascular risk factors during follow-up for DTC.
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